Pomerantz LLP investigates GSK securities fraud claims.
PorAinvest
martes, 2 de septiembre de 2025, 10:05 am ET1 min de lectura
CNC--
Pomerantz LLP has initiated an investigation into GSK plc (GSK) for potential securities fraud or unlawful business practices. The probe centers on the company's July 2025 press release, which announced a negative FDA advisory committee vote on its Blenrep drug. This announcement resulted in a 4.73% drop in GSK's American Depositary Receipt (ADR) price.
Investors who held GSK shares during the time of the Blenrep announcement are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation is ongoing and aims to determine if the company engaged in any fraudulent or illegal activities related to the Blenrep announcement.
Despite the ongoing investigation, GSK has received a significant boost with the UK approval of Blujepa, a novel oral antibiotic designed to treat uncomplicated urinary tract infections. This approval marks a milestone in GSK's innovative portfolio, as it introduces the first new class of oral antibiotics in several decades. Analysts are cautiously optimistic about the implications of this approval. The average one-year price target for GSK plc is $38.39, with predictions ranging from $45.00 to $33.91, suggesting a potential downside of 3.81% from the current price of $39.91.
GuruFocus estimates suggest a GF Value of $44.64 for GSK plc in one year, projecting an upside potential of 11.85% from the current price. Despite the positive outlook, investors should remain vigilant due to the ongoing investigation by Pomerantz LLP.
References:
[1] https://www.gurufocus.com/news/3083978/gsk-gsk-receives-uk-approval-for-new-antibiotic-blujepa
GSK--
Pomerantz LLP is investigating claims of securities fraud against GSK plc, focusing on the company's announcement of a negative FDA advisory committee vote for its drug Blenrep. The news led to a 4.73% drop in GSK's American Depositary Receipt price. Investors who held GSK shares are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
September 02, 2025Pomerantz LLP has initiated an investigation into GSK plc (GSK) for potential securities fraud or unlawful business practices. The probe centers on the company's July 2025 press release, which announced a negative FDA advisory committee vote on its Blenrep drug. This announcement resulted in a 4.73% drop in GSK's American Depositary Receipt (ADR) price.
Investors who held GSK shares during the time of the Blenrep announcement are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation is ongoing and aims to determine if the company engaged in any fraudulent or illegal activities related to the Blenrep announcement.
Despite the ongoing investigation, GSK has received a significant boost with the UK approval of Blujepa, a novel oral antibiotic designed to treat uncomplicated urinary tract infections. This approval marks a milestone in GSK's innovative portfolio, as it introduces the first new class of oral antibiotics in several decades. Analysts are cautiously optimistic about the implications of this approval. The average one-year price target for GSK plc is $38.39, with predictions ranging from $45.00 to $33.91, suggesting a potential downside of 3.81% from the current price of $39.91.
GuruFocus estimates suggest a GF Value of $44.64 for GSK plc in one year, projecting an upside potential of 11.85% from the current price. Despite the positive outlook, investors should remain vigilant due to the ongoing investigation by Pomerantz LLP.
References:
[1] https://www.gurufocus.com/news/3083978/gsk-gsk-receives-uk-approval-for-new-antibiotic-blujepa
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios